Catalyst Pharmaceuticals, Inc. (CPRX) — Fair Value Analysis

Base-case fair value (P50): $34.85 · Current price: $31.15 · Verdict: Fairly Valued

The Verdict on CPRX

CATALYST PHARMACEUTICALS INC (CPRX) is currently assessed as Fairly Valued by our Monte Carlo simulations, despite offering a notable potential upside. With a current price of $31.15, our median fair value (P50) for CPRX stands at $34.85. This +11.9% difference suggests the stock is reasonably priced in the market, reflecting a balance between current valuation and potential growth factors. While there's a clear premium to the current trading price, our methodology categorizes this as "Fairly Valued," indicating that the market largely reflects known information and expected trajectories without significant mispricing.

How CPRX stacks up against peers

CPRX holds a "strong" quality tier, indicating robust operational and financial health when compared to its sector peers. This strong fundamental positioning provides a solid foundation for the company's valuation and contributes to its Fairly Valued assessment. A "strong" quality tier suggests that the company possesses attributes—such as efficient operations or healthy balance sheets—that differentiate it positively within its sector. This operational excellence supports the $34.85 median fair value, suggesting that the underlying business quality justifies the current pricing and the +11.9% upside potential.

What this means for investors

For investors considering CPRX, the "Fairly Valued" verdict and the $34.85 median fair value (P50) indicate that the stock is priced appropriately given its fundamentals and a range of simulated market conditions. While the +11.9% upside to the P50 provides a positive outlook, a prudent approach would involve understanding the full distribution of potential outcomes, including both downside and bull-case scenarios. FairCurve's detailed Monte Carlo analysis models thousands of forward scenarios to capture this complete picture. To view the full bear and bull distribution and track CPRX's fair value as new fundamentals are released, sign up for a free FairCurve account.